These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33436392)

  • 1. Refractory alveolar rhabdomyosarcoma in an 11-year-old male.
    Ricker CA; Woods AD; Simonson W; Lathara M; Srinivasa G; Rudzinski ER; Mansoor A; Irwin RG; Keller C; Berlow NE
    Cold Spring Harb Mol Case Stud; 2021 Feb; 7(1):. PubMed ID: 33436392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).
    Gallego S; Zanetti I; Orbach D; Ranchère D; Shipley J; Zin A; Bergeron C; de Salvo GL; Chisholm J; Ferrari A; Jenney M; Mandeville HC; Rogers T; Merks JHM; Mudry P; Glosli H; Milano GM; Ferman S; Bisogno G;
    Cancer; 2018 Aug; 124(15):3201-3209. PubMed ID: 29797665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.
    Canner JA; Sobo M; Ball S; Hutzen B; DeAngelis S; Willis W; Studebaker AW; Ding K; Wang S; Yang D; Lin J
    Br J Cancer; 2009 Sep; 101(5):774-81. PubMed ID: 19707204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.
    Williamson D; Missiaglia E; de Reyniès A; Pierron G; Thuille B; Palenzuela G; Thway K; Orbach D; Laé M; Fréneaux P; Pritchard-Jones K; Oberlin O; Shipley J; Delattre O
    J Clin Oncol; 2010 May; 28(13):2151-8. PubMed ID: 20351326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma.
    Seitz G; Warmann SW; Vokuhl CO; Heitmann H; Treuner C; Leuschner I; Fuchs J
    Pediatr Surg Int; 2007 May; 23(5):431-9. PubMed ID: 17211591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
    Rudzinski ER; Anderson JR; Chi YY; Gastier-Foster JM; Astbury C; Barr FG; Skapek SX; Hawkins DS; Weigel BJ; Pappo A; Meyer WH; Arnold MA; Teot LA; Parham DM
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28521080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance.
    Danielli SG; Porpiglia E; De Micheli AJ; Navarro N; Zellinger MJ; Bechtold I; Kisele S; Volken L; Marques JG; Kasper S; Bode PK; Henssen AG; Gürgen D; Delattre O; Surdez D; Roma J; Bühlmann P; Blau HM; Wachtel M; Schäfer BW
    Sci Adv; 2023 Feb; 9(6):eade9238. PubMed ID: 36753540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case report for an adolescent with germline RET mutation and alveolar rhabdomyosarcoma.
    Crawford KA; Berlow NE; Tsay J; Lazich M; Mancini M; Noakes C; Huang T; Keller C
    Cold Spring Harb Mol Case Stud; 2020 Jun; 6(3):. PubMed ID: 32532875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.
    Sorensen PH; Lynch JC; Qualman SJ; Tirabosco R; Lim JF; Maurer HM; Bridge JA; Crist WM; Triche TJ; Barr FG
    J Clin Oncol; 2002 Jun; 20(11):2672-9. PubMed ID: 12039929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
    Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
    Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death.
    Ommer J; Selfe JL; Wachtel M; O'Brien EM; Laubscher D; Roemmele M; Kasper S; Delattre O; Surdez D; Petts G; Kelsey A; Shipley J; Schäfer BW
    Cancer Res; 2020 Feb; 80(4):832-842. PubMed ID: 31888889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary alveolar rhabdomyosarcoma of bone.
    Tordecilla C J; Mosso Ch C; Franco S C; Díaz P E; Lobos R G
    Andes Pediatr; 2021 Jun; 92(3):440-445. PubMed ID: 34479252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A rare case of metastatic paraspinal rhabdomyosarcoma presenting with proptosis in an adult patient.
    Chanda UL; Knapp C
    Orbit; 2024 Apr; 43(2):280-282. PubMed ID: 36131600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?
    Anderson J; Gordon T; McManus A; Mapp T; Gould S; Kelsey A; McDowell H; Pinkerton R; Shipley J; Pritchard-Jones K;
    Br J Cancer; 2001 Sep; 85(6):831-5. PubMed ID: 11556833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment and characterization of a novel alveolar rhabdomyosarcoma cell line, NCC-aRMS1-C1.
    Sin Y; Yoshimatsu Y; Noguchi R; Tsuchiya R; Sei A; Ono T; Toki S; Kobayashi E; Arakawa A; Sugiyama M; Yoshida A; Kawai A; Kondo T
    Hum Cell; 2020 Oct; 33(4):1311-1320. PubMed ID: 32715445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alveolar rhabdomyosarcoma mimicking acute leukemia at presentation.
    Liapis K; Alevizopoulos N; Delimpasi S; Apostolidis J; Harhalakis N; Rontogianni D; Nikiforakis E
    J BUON; 2009; 14(3):529-30. PubMed ID: 19810151
    [No Abstract]   [Full Text] [Related]  

  • 17. Synchronous bifocal alveolar rhabdomyosarcoma: a case report.
    Siegel HJ; Connor GS; Lee D; Lopez-Ben R; Kelly DR
    J Bone Joint Surg Br; 2006 Jul; 88(7):955-8. PubMed ID: 16799004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group.
    Arnold MA; Anderson JR; Gastier-Foster JM; Barr FG; Skapek SX; Hawkins DS; Raney RB; Parham DM; Teot LA; Rudzinski ER; Walterhouse DO
    Pediatr Blood Cancer; 2016 Apr; 63(4):634-9. PubMed ID: 26756883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of PAX-FKHR fusion status in alveolar rhabdomyosarcoma: a report from the cooperative soft tissue sarcoma study group (CWS).
    Stegmaier S; Poremba C; Schaefer KL; Leuschner I; Kazanowska B; Békássy AN; Bielack SS; Klingebiel T; Koscielniak E
    Pediatr Blood Cancer; 2011 Sep; 57(3):406-14. PubMed ID: 21254373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Manifestation of alveolar rhabdomyosarcoma as primary cutaneous lesions in a neonate with Beckwith-Wiedemann syndrome.
    Kuroiwa M; Sakamoto J; Shimada A; Suzuki N; Hirato J; Park MJ; Sotomatsu M; Hayashi Y
    J Pediatr Surg; 2009 Mar; 44(3):e31-5. PubMed ID: 19302842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.